Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).

Article  CAS  PubMed  Google Scholar 

Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

Article  CAS  PubMed  Google Scholar 

Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 7, a016600 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Pettitt, S. J. et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475–1488 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Langelier, M.-F., Lin, X., Zha, S. & Pascal, J. M. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Sci. Adv. 9, eadf7175 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).

Article  Google Scholar 

Jiang, L. et al. A quantitative proteome map of the human body. Cell 183, 269–283.e19 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).

Article  Google Scholar 

Gonçalves, E. et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40, 835–849.e8 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92–100 (2024).

Article  CAS  PubMed  Google Scholar 

Pacini, C. et al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell 42, 301–316.e9 (2024). This article provides a recent systematic analysis of genetic dependencies in 930 cancer cell lines, linking biomarkers with potential therapeutic targets and analysing the prevalence of these biomarkers in patient populations.

Article  CAS  PubMed  Google Scholar 

Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503–508 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).

Article  CAS  PubMed  Google Scholar 

Chen, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551–556 (2019). References 16 and 17 both show for the first time using CRISPR–Cas9 screens that WRN is synthetically lethal in MSI cancers.

Article  Google Scholar 

Picco, G. et al. Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy and immunotherapy. Cancer Discov. 11, 1923–1937 (2021).

Article  CAS  PubMed  Google Scholar 

US National Library of Medicine. ClinicalTrials.gov https://classic.clinicaltrials.gov/ct2/show/NCT06004245.

Adams, D. & McDermott, U. Editorial overview: cancer genomics: kill it. Kill it dead. Curr. Opin. Genet. Dev. 24, v–vi (2014).

Article  CAS  PubMed  Google Scholar 

O’Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613–623 (2017).

Article  PubMed  Google Scholar 

Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 564–576 (2018).

Article  CAS  PubMed  Google Scholar 

Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug Discov. 19, 23–38 (2020).

Article  CAS  PubMed  Google Scholar 

Setton, J. et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 11, 1626–1635 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schäffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E. & Lee, J. S. A systematic analysis of the landscape of synthetic lethality-driven precision oncology. Med 5, 73–89.e9 (2024). This article provides a systematic analysis of SL therapies in clinical trials, revealing that most of these therapies involve genes in the DDR and that success rates for SL trials are generally higher than for non-SL therapies.

Article  PubMed  Google Scholar 

Ryan, C. J., Mehta, I., Kebabci, N. & Adams, D. J. Targeting synthetic lethal paralogs in cancer. Trends Cancer Res. 9, 397–409 (2023).

Article  CAS  Google Scholar 

Ryan, C. J., Devakumar, L. P. S., Pettitt, S. J. & Lord, C. J. Complex synthetic lethality in cancer. Nat. Genet. 55, 2039–2048 (2023).

Article  CAS  PubMed  Google Scholar 

Ross, J. S. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368 (2009).

Article  CAS  PubMed  Google Scholar 

Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3080 (2008).

Article  CAS  PubMed  Google Scholar 

Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the ‘undruggable’ cancer targets. Nat. Rev. Cancer 17, 502–508 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, J. et al. SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. Database 2022, baac030 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Gökbağ, B. et al. SLKB: synthetic lethality knowledge base. Nucleic Acids Res. 52, D1418–D1428 (2024).

Article  PubMed